|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,096 GBX | -0.12% |
|
-1.80% | +14.11% |
Dec 21 (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease.
(Reporting by Puyaan Singh, Mariam Sunny and Bhanvi Satija in Bengaluru; Editing by Tasim Zahid)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 12,096 GBX | -0.12% | -1.80% | 239B | ||
| 38.72 USD | +3.78% | -0.21% | 5.44B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +14.11% | 239B | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B | |
| -0.90% | 162B |
ASTRAZENECA PLC 
